The hypertension optimal treatment study: What did it give us?

被引:2
作者
Bryg R.J. [1 ]
Graettinger W.F. [1 ]
机构
[1] Division of Cardiology, Department of Medicine, University of Nevada School of Medicine, Reno, NV 89520
关键词
Felodipine; Major Cardiovascular Event; Target Blood Pressure; Hypertension Optimal Treatment; Blood Pressure Group;
D O I
10.1007/s11906-999-0043-4
中图分类号
学科分类号
摘要
The Hypertension Optimal Treatment study was a large, randomized, multicenter study to determine the answers to two questions: 1) what is the optimal target blood pressure to be sought in the treatment of patients with moderate hypertension? and 2) does low dose aspirin therapy decrease morbidity and mortality in patients with hypertension? After 3.8 years of follow-up for the almost 19,000 patients, the following conclusions from the study could be ascertained 1) lowering diastolic blood pressure in patients with diabetes to levels below 80 mm Hg decreases the risk of major cardiovascular events and cardiovascular mortality compared with lowering it to "normal" (< 90 mm Hg) levels It may lower total mortality, but this study was not powered for this end point; 2) aspirin therapy, in patients with hypertension, is safe and decreases major cardiovascular events and acute myocardial infarction; 3) there does not appear to be an additional effect on cardiovascular mortality or overall mortality below that observed with a reduction of diastolic blood pressure to less than 90 mm Hg for the population as a whole; and 4) the lowest cardiovascular event rate for the population as a whole was achieved at a diastolic blood pressure of 83 mm Hg. Several limitations to this study exist, including the low event rate achieved and the generalizability of this study to the average nondiabetic patient with hypertension seen in clinical practice. Copyright © 1999 by Current Science Inc.
引用
收藏
页码:337 / 341
页数:4
相关论文
共 30 条
[1]  
Hansson L., Zanchetti A., Carruthers S.G., Et al., Effects o intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial, Lancet, 351, pp. 1755-1762, (1998)
[2]  
Hansson L., Zanchetti A., The Hypertension Optimal Treatment (HOT) Study: 12-month data on blood pressure and tolerability with special reference to age and gender, Blood Press, 4, pp. 313-319, (1995)
[3]  
Hansson L., Zanchetti A., The Hypertension Optimal Treatment (HOT) study: Patient characteristics: Randomization, risk profile and early blood pressure results, Blood Press, 3, pp. 322-327, (1994)
[4]  
Hansson L., The Hypertension Optimal Treatment Study (The HOT Study), Blood Press, 2, pp. 62-68, (1993)
[5]  
Wiklund I., Halling K., Ryden-Bergsten T., Et al., Does lowering the blood pressure improve the mood? Quality-of-life results from the Hypertension Optimal Treatment (HOT) study, Blood Press, 6, pp. 357-364, (1997)
[6]  
Hansson L., Zanchetti A., The Hypertension Optimal Treatment (HOT) study: 24 month data on blood pressure and tolerability, Blood Press, 6, pp. 313-317, (1997)
[7]  
Julius S., The Hypertension Optimal Treatment (HOT) Study in the United States, Am J Hypertens, 9, (1996)
[8]  
Chalmers J., The HOT Study: Design and cost of major blood pressure trials, Blood Press, 3, pp. 276-278, (1994)
[9]  
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension - Final results of the Systolic Hyperten sion in the Elderly Program, JAMA, 265, pp. 3255-3264, (1991)
[10]  
Graettinger W.F., Weber M.A., The Hypertension Syndrome: More than increased blood pressure, Modern Medicine, 60, pp. 118-126, (1992)